{"pmid":32436995,"title":"The Potential of Memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.","text":["The Potential of Memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.","SARS-CoV-2 appears to have neurotropic aspects with neurotoxicity through interaction with ACE2 in the medullary brainstem, causing glutamate toxicity in the rostral ventrolateral medulla (RVLM), increased sympathetic tone, hypertension and pulmonary capillary leakage of fluid into the alveoli, resulting in acute respiratory distress syndrome (ARDS). Memantine, a moderate affinity, uncompetitive N-Methyl-D-aspartic acid (NMDA) receptor antagonist which prevents excess calcium entry into cells is commonly utilized in treating patients with Alzheimer's disease, and may inhibit the neurotoxicity induced by SARS-CoV-2 in the medullary brain stem to avoid development of ARDS. Memantine and related adamantine such as amantadine, which is utilized in Parkinson's disease and influenza, may have some anti-viral potential as well. Memantine and similar adamantines may have potential as repurposed medicines for treating Covid19 with inhibition of neurotoxicity, ARDS and viral replication, since Memantine appears to be lysosomotropic. This article is protected by copyright. All rights reserved.","J Med Virol","Brenner, Steven R","32436995"],"abstract":["SARS-CoV-2 appears to have neurotropic aspects with neurotoxicity through interaction with ACE2 in the medullary brainstem, causing glutamate toxicity in the rostral ventrolateral medulla (RVLM), increased sympathetic tone, hypertension and pulmonary capillary leakage of fluid into the alveoli, resulting in acute respiratory distress syndrome (ARDS). Memantine, a moderate affinity, uncompetitive N-Methyl-D-aspartic acid (NMDA) receptor antagonist which prevents excess calcium entry into cells is commonly utilized in treating patients with Alzheimer's disease, and may inhibit the neurotoxicity induced by SARS-CoV-2 in the medullary brain stem to avoid development of ARDS. Memantine and related adamantine such as amantadine, which is utilized in Parkinson's disease and influenza, may have some anti-viral potential as well. Memantine and similar adamantines may have potential as repurposed medicines for treating Covid19 with inhibition of neurotoxicity, ARDS and viral replication, since Memantine appears to be lysosomotropic. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Brenner, Steven R"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436995","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26030","keywords":["ards","memantine","neurotrophic","sars-cov-2","hypertension","neurotoxicity"],"e_drugs":["Memantine","Glutamic Acid","Adamantane","N-Methylaspartate","Amantadine","Calcium"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393744412672,"score":9.490897,"similar":[{"pmid":32388458,"title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.","text":["Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.","Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease.","Mult Scler Relat Disord","Rejdak, Konrad","Grieb, Pawel","32388458"],"abstract":["Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease."],"journal":"Mult Scler Relat Disord","authors":["Rejdak, Konrad","Grieb, Pawel"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388458","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.msard.2020.102163","keywords":["adamantanes","amantadine","covid-19","cognitive impairment","memantine","multiple sclerosis","pd","protection","sars-cov-2"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666428892563374081,"score":408.5353},{"pmid":32361028,"pmcid":"PMC7191300","title":"\"Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment \".","text":["\"Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment \".","SARS-coronavirus 2 is the causal agent of the COVID-19 outbreak. SARS-Cov-2 entry into a cell is dependent upon binding of the viral spike (S) protein to cellular receptor and on cleavage of the spike protein by the host cell proteases such as Cathepsin L and Cathepsin B. CTSL/B are crucial elements of lysosomal pathway and both enzymes are almost exclusively located in the lysosomes. CTSL disruption offers potential for CoVID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increase pH in the lysosomes). We have conducted a high throughput drug screen gene expression analysis to identify compounds that would downregulate the expression of CTSL/CTSB. One of the top significant results shown to downregulate the expression of the CTSL gene is amantadine (10uM). Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease. It is available as a generic drug. Amantadine in addition to downregulating CTSL appears to further disrupt lysosomal pathway, hence, interfering with the capacity of the virus to replicate. It acts as a lysosomotropic agent altering the CTSL functional environment. We hypothesize that amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic decreasing the replication and infectivity of the virus likely leading to better clinical outcomes. Clinical studies will be needed to examine the therapeutic utility of amantadine in COVID-19 infection.","Int J Antimicrob Agents","Smieszek, Sandra P","Przychodzen, Bart P","Polymeropoulos, Mihael H","32361028"],"abstract":["SARS-coronavirus 2 is the causal agent of the COVID-19 outbreak. SARS-Cov-2 entry into a cell is dependent upon binding of the viral spike (S) protein to cellular receptor and on cleavage of the spike protein by the host cell proteases such as Cathepsin L and Cathepsin B. CTSL/B are crucial elements of lysosomal pathway and both enzymes are almost exclusively located in the lysosomes. CTSL disruption offers potential for CoVID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increase pH in the lysosomes). We have conducted a high throughput drug screen gene expression analysis to identify compounds that would downregulate the expression of CTSL/CTSB. One of the top significant results shown to downregulate the expression of the CTSL gene is amantadine (10uM). Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease. It is available as a generic drug. Amantadine in addition to downregulating CTSL appears to further disrupt lysosomal pathway, hence, interfering with the capacity of the virus to replicate. It acts as a lysosomotropic agent altering the CTSL functional environment. We hypothesize that amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic decreasing the replication and infectivity of the virus likely leading to better clinical outcomes. Clinical studies will be needed to examine the therapeutic utility of amantadine in COVID-19 infection."],"journal":"Int J Antimicrob Agents","authors":["Smieszek, Sandra P","Przychodzen, Bart P","Polymeropoulos, Mihael H"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361028","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ijantimicag.2020.106004","keywords":["amantadine","covid19","cathepsin l (ctsl)","drug screen","gene expression","lysosomotropic agents"],"locations":["CTSL"],"e_drugs":["Amantadine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495897305088,"score":358.60315},{"pmid":32311651,"pmcid":"PMC7159862","title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.","text":["Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.","The novel coronavirus disease 2019 (COVID-19) outbreak once again demonstrated the importance of the renin-angiotensin system (RAS) in patients with diabetes. Activation of the RAS increases in patients with diabetes. The virus attaches to the ACE2 enzyme at low cytosolic pH values and enters into the cell and causes infection. Especially in the presence of diabetes mellitus and accompanying comorbid conditions such as hypertension, obesity, old age, and smoking, cytosolic pH is low, thus the virus easily may enter the cell by attaching to ACE2. ACEIs and ARBs lead to a reduction in angiotensin II level by increasing the ACE2 level, thus they cause a low cytosolic pH. Increased cardiac ACE2 levels due to ACEIs and ARBs can trigger cardiac arrhythmias and myocarditis by causing the virus to easily enter the heart tissue. There is ACE2 activity in the rostral ventrolateral medulla in the brain stem. The release of angiotensin 1-7 in the brain stem leads to the activation of the sympathetic nervous system. This activation causes systemic vasoconstriction and the patient's blood pressure increases. The most important event is the increased sympathetic activity via the central stimulation, this activity increases pulmonary capillary leaking, causing the ARDS. As the cytosolic pH, which is already low in patients with diabetes will decrease further with the mechanisms mentioned above, the viral load will increase and the infection will be exacerbated. As a result, the use of ACEIs and ARBs in patients with diabetes can lead to increased morbidity and mortality of COVID-19.","Diabetes Metab Syndr","Cure, Erkan","Cumhur Cure, Medine","32311651"],"abstract":["The novel coronavirus disease 2019 (COVID-19) outbreak once again demonstrated the importance of the renin-angiotensin system (RAS) in patients with diabetes. Activation of the RAS increases in patients with diabetes. The virus attaches to the ACE2 enzyme at low cytosolic pH values and enters into the cell and causes infection. Especially in the presence of diabetes mellitus and accompanying comorbid conditions such as hypertension, obesity, old age, and smoking, cytosolic pH is low, thus the virus easily may enter the cell by attaching to ACE2. ACEIs and ARBs lead to a reduction in angiotensin II level by increasing the ACE2 level, thus they cause a low cytosolic pH. Increased cardiac ACE2 levels due to ACEIs and ARBs can trigger cardiac arrhythmias and myocarditis by causing the virus to easily enter the heart tissue. There is ACE2 activity in the rostral ventrolateral medulla in the brain stem. The release of angiotensin 1-7 in the brain stem leads to the activation of the sympathetic nervous system. This activation causes systemic vasoconstriction and the patient's blood pressure increases. The most important event is the increased sympathetic activity via the central stimulation, this activity increases pulmonary capillary leaking, causing the ARDS. As the cytosolic pH, which is already low in patients with diabetes will decrease further with the mechanisms mentioned above, the viral load will increase and the infection will be exacerbated. As a result, the use of ACEIs and ARBs in patients with diabetes can lead to increased morbidity and mortality of COVID-19."],"journal":"Diabetes Metab Syndr","authors":["Cure, Erkan","Cumhur Cure, Medine"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311651","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.dsx.2020.04.019","keywords":["angiotensin converting enzyme inhibitors","angiotensin receptor antagonists","diabetes mellitus","novel coronavirus disease 2019 (covid-19)","renin-angiotensin system"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491231141888,"score":334.21722},{"pmid":32250244,"pmcid":"PMC7198232","title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","text":["Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) has implicated the renin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus disease-19 (COVID-19). The angiotensin converting enzyme-1-angiotensin II-angiotensin AT1 receptor pathway contributes to the pathophysiology of ARDS, whereas activation of the ACE-2-angiotensin(1-7)-angiotensin AT2 receptor and the ACE-2-angiotensin(1-7)-Mas receptor pathways have been shown to be protective. Here we propose and discuss therapeutic considerations how to increase soluble ACE-2 in plasma in order for ACE-2 to capture and thereby inactivate SARS-CoV-2. This could be achieved by administering recombinant soluble ACE-2. We also discuss why and how ACEIs and ARBs provide cardiovascular, renal and also pulmonary protection in SARS-CoV-2- associated ARDS. Discontinuing these medications in COVID-19 patients may therefore potentially be harmful.","Elife","Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias","32250244"],"abstract":["The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) has implicated the renin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus disease-19 (COVID-19). The angiotensin converting enzyme-1-angiotensin II-angiotensin AT1 receptor pathway contributes to the pathophysiology of ARDS, whereas activation of the ACE-2-angiotensin(1-7)-angiotensin AT2 receptor and the ACE-2-angiotensin(1-7)-Mas receptor pathways have been shown to be protective. Here we propose and discuss therapeutic considerations how to increase soluble ACE-2 in plasma in order for ACE-2 to capture and thereby inactivate SARS-CoV-2. This could be achieved by administering recombinant soluble ACE-2. We also discuss why and how ACEIs and ARBs provide cardiovascular, renal and also pulmonary protection in SARS-CoV-2- associated ARDS. Discontinuing these medications in COVID-19 patients may therefore potentially be harmful."],"journal":"Elife","authors":["Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250244","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.7554/eLife.57278","keywords":["ace","ace inhibitor","ace inhibitors","ace-2","aceis","arbs","ards","acute respiratory distress syndrome","covid-19","raas","sars","sars-cov-2","angiotensin","angiotensin receptor antagonists","angiotensin receptor blocker","angiotensin-converting enzyme-1","angiotensin-converting enzyme-2","arterial hypertension","cardiovascular","coronavirus","human biology","infection","medicine","renin-angiotensin-aldosterone system","therapy","treatment","virus"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490960609281,"score":218.43835},{"pmid":32464584,"title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.","text":["The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.","BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS. OBJECTIVE: To examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic.","Mult Scler Relat Disord","Baker, David","Amor, Sandra","Kang, Angray S","Schmierer, Klaus","Giovannoni, Gavin","32464584"],"abstract":["BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS. OBJECTIVE: To examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic."],"journal":"Mult Scler Relat Disord","authors":["Baker, David","Amor, Sandra","Kang, Angray S","Schmierer, Klaus","Giovannoni, Gavin"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464584","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.msard.2020.102174","topics":["Prevention","Mechanism","Treatment"],"weight":1,"_version_":1668079521343995904,"score":210.8001}]}